Astrocytoma, Grade IV Clinical Trials

7 recruiting

Frequently Asked Questions

Common questions about Astrocytoma, Grade IV clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Not Applicable

UNIty-Based MR-Linac Guided Adaptive RadioThErapy for High GraDe Glioma-4

Glioblastoma (GBM)Astrocytoma, Grade IV
Sunnybrook Health Sciences Centre60 enrolled1 locationNCT07459101
Recruiting
Phase 3

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

GliomaAstrocytoma, IDH-Mutant, Grade 2Astrocytoma, Grade IV+5 more
Nuvation Bio Inc.365 enrolled45 locationsNCT05303519
Recruiting
Phase 1

Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy

Recurrent Astrocytoma, IDH-Mutant, Grade 4Recurrent Glioblastoma, IDH-WildtypeAstrocytoma, Grade IV
Mayo Clinic20 enrolled1 locationNCT05789394
Recruiting
Phase 2

Study of Olutasidenib and Temozolomide in HGG

Metastatic Brain TumorIDH1 MutationAstrocytoma, Grade IV+16 more
Rigel Pharmaceuticals60 enrolled18 locationsNCT06161974
Recruiting
Phase 1Phase 2

T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma

Glioblastoma MultiformeAstrocytoma, Grade IV
Queensland Institute of Medical Research58 enrolled4 locationsNCT06157541
Recruiting

The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)

Brain NeoplasmsGlioblastomaGlioblastoma, IDH-wildtype+9 more
Jasper Gerritsen784 enrolled8 locationsNCT06118723
Recruiting
Not Applicable

The SAFE-Trial: Awake Craniotomy Versus Surgery Under General Anesthesia for Glioblastoma Patients.

Brain NeoplasmsBrain TumorBrain Cancer+4 more
Jasper Gerritsen246 enrolled5 locationsNCT03861299